BFS
LGND icon

Bare Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Bare Financial Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Buy
78
+25
+47% +$5.89K 0.01% 196
2026
Q1 		$10.6K Buy
53
+12
+29% +$2.37K ﹤0.01% 320
2025
Q4 		$7.75K Hold
41
– – ﹤0.01% 343
2025
Q3 		$7.26K Buy
41
+31
+310% +$4.61K ﹤0.01% 371
2025
Q2 		$1.14K Buy
10
+3
+43% +$321 ﹤0.01% 881
2025
Q1 		$736 Buy
+7
New +$792 ﹤0.01% 630

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bare Financial Services's LGND Position: Q2 2026 in Review

Bare Financial Services increased its Ligand Pharmaceuticals (LGND) stake by 47% in Q2 2026, buying an estimated $5.89K and bringing the position to 78 shares worth $24.7K. The position accounts for 0.01% of the portfolio, ranked #196.

Bare Financial Services first reported a position in LGND in Q1 2025 and has held it in 6 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Bare Financial Services held 78 shares of Ligand Pharmaceuticals worth $24.7K as of Q2 2026.
  • Bare Financial Services bought 25 Ligand Pharmaceuticals shares in Q2 2026, an estimated $5.89K.
  • Ligand Pharmaceuticals made up 0.01% of Bare Financial Services's portfolio in Q2 2026, its #196 holding.
  • Bare Financial Services first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.